NCT01412398

Fosrenol Post-marketing Surveillance for Continuous Cyclic Peritoneal Dialysis in Japan

Special Drug Use Investigation of Fosrenol (Investigation for Patients With Continuous Ambulatory Peritoneal Dialysis)

• Status: Completed
• Phase: —
• Study type: Observational
• Enrollment: 446 (actual)
• Sponsor: Bayer · Industry
• Sex: All
• Age: 13 Years
• Healthy volunteers: Not accepted

Summary

This study is a regulatory post marketing surveillance in Japan, and it is a local prospective and observational study of patients in continuous ambulatory peritoneal dialysis (CAPD) who have received Fosrenol for hyperphosphatemia. The objective of this study is to assess safety and efficacy of using Fosrenol in clinical practice. This study is also all case investigation of which the enrollment period is one year, and all patients in CAPD who received Fosrenol for hyperphosphatemia will be recruited and followed one year.

Conditions

• Hyperphosphatemia

Interventions

Type	Name	Description
DRUG	Lanthanum Carbonate (Fosrenol, BAY77-1931) - chewable tablet	Patients in CAPD who have received Fosrenol for hyperphosphatemia

Timeline

• Start date: 2009-04-07
• Primary completion: 2014-04-08
• Completion: 2016-09-01
• First posted: 2011-08-09
• Last updated: 2018-01-19

Locations

1 site across 1 country: Japan